Allogene Therapeutics, Inc.
ALLO
$1.44
-$0.09-5.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -100.00% | -76.84% | 26.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -100.00% | -100.00% | -76.84% | 26.47% |
| Cost of Revenue | -17.57% | -11.42% | -11.49% | -20.84% | -23.39% |
| Gross Profit | 17.56% | 11.39% | 11.45% | 20.81% | 23.40% |
| SG&A Expenses | -12.53% | -9.61% | -10.17% | -9.02% | -11.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.32% | -10.97% | -11.17% | -18.15% | -20.71% |
| Operating Income | 16.31% | 10.95% | 11.14% | 18.13% | 20.71% |
| Income Before Tax | 25.35% | 15.37% | 13.83% | 21.43% | 17.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 25.20% | 15.22% | 13.68% | 21.29% | 17.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.20% | 15.22% | 13.68% | 21.29% | 17.64% |
| EBIT | 16.31% | 10.95% | 11.14% | 18.13% | 20.71% |
| EBITDA | 16.66% | 10.93% | 11.33% | 18.80% | 21.62% |
| EPS Basic | 37.10% | 31.15% | 31.96% | 36.80% | 32.60% |
| Normalized Basic EPS | 30.52% | 29.29% | 32.38% | 37.45% | 39.92% |
| EPS Diluted | 37.10% | 31.15% | 31.96% | 36.80% | 32.60% |
| Normalized Diluted EPS | 30.52% | 29.29% | 32.38% | 37.45% | 39.92% |
| Average Basic Shares Outstanding | 17.68% | 22.86% | 26.57% | 24.16% | 22.14% |
| Average Diluted Shares Outstanding | 17.68% | 22.86% | 26.57% | 24.16% | 22.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |